Featured Research

from universities, journals, and other organizations

Researchers Discover Ways The Ulcer/Cancer Bug Can Trigger Disease

Date:
April 6, 1998
Source:
Washington University School Of Medicine
Summary:
A mouse with a human gene has revealed why some people who harbor the peptic ulcer bacterium get sick while others don't. If the stomach lining provides toeholds for the bacterium, it may draw the immune system's friendly fire.

St. Louis, March 24 -- A mouse with a human gene has revealed why some people who harbor the peptic ulcer bacterium get sick while others don't. If the stomach lining provides toeholds for the bacterium, it may draw the immune system's friendly fire.

"If the right combination of circumstances occurs -- first, you're unfortunate enough to be infected with a bacterial strain that can bind to the cells lining your stomach and, second, the bacterium contains molecules on its surface that resemble some of those on your stomach cells -- the destiny of the infection may be skewed toward autoantibody production, loss of acid-producing cells and possibly neoplasia," says lead researcher Jeffrey I. Gordon, M.D., the Alumni Professor and head of the Department of Molecular Biology and Pharmacology at Washington University School of Medicine in St. Louis.

Researchers in Gordon's lab describe their findings in the March 31 issue of Proceedings of the National Academy of Sciences. First authors are postdoctoral fellow Janaki L. Guruge, Ph.D., and Per Falk, M.D., Ph.D., adjunct assistant professor of molecular biology and pharmacology at the School of Medicine and now associate director of molecular biology at the Swedish pharmaceutical company ASTRA Hässle.

Half of the world's people are colonized with Helicobacter pylori. Most have few symptoms -- some gastric inflammation, perhaps, before an apparently harmonious relationship sets in that can last for decades. But 10 to 20 percent of infected individuals are not so lucky. Some get ulcers, and others develop progressive inflammation of the stomach and lose acid-producing cells. This increases their risk for stomach cancer, which is common in countries where H. pylori infection is rife.

"This is a rather extraordinary example of a bacterium that can be relatively harmless in some people and cause cancer in others," Gordon says. "The challenge is to identify patients who are at risk for developing more serious disease."

Look into the stomach of an infected person who has severe gastritis or ulcers, and you'll see H. pylori associated with cells that line the stomach. The bacterium is able to produce molecules that allow it to attach to these stomach cells. In laboratory experiments, scientists have identified several molecular receptors that can serve as potential sites for bacterial attachment. "We wanted to find out whether -- and how -- attachment could alter the outcome of infection," Gordon says.

Australian scientists fingered H. pylori as the culprit of peptic ulcers in the 1980s, but the lack of genetically well-defined animal models has hampered attempts to understand how the organism causes disease. "Cultured stomach cells can't reveal how you would respond if H. pylori stuck to your stomach lining," Falk says.

In 1993, Falk and another Swedish scientist at Washington University, Thomas Borén, D.D.S., Ph.D., discovered that H. pylori can attach to a molecule called Lewis b (Leb) on stomach lining cells. This molecule also decorates the red blood cells of people with the Leb blood group.

In Gordon's lab, Falk introduced the human Leb gene into a mouse. He manipulated the gene so it was produced in cells that line the animal's stomach. Mice without the human Leb gene served as normal controls.

Both groups of mice were exposed to H. pylori strains retrieved from Peruvian patients with gastritis. The Leb blood group antigen is commonly found in Peruvians, and most H. pylori strains from Peru are able to bind to Leb. Guruge found that both groups of mice -- those with and those without Leb -- became infected with H. pylori easily and for long periods of time. The bacteria attached to the stomach epithelium only in animals with human Leb, however. In the control mice that lacked Leb, they simply parked in the gastric mucus.

This difference in location affected the mouse's immune response. Guruge noticed that the mouse made antibodies against H. pylori carbohydrates when the bacterium attached to the stomach lining. As it turned out, these bacterial carbohydrates resembled carbohydrates that a mouse's own acid-producing parietal cells normally produce.

Faced with this molecular mimicry, the immune system attacked the mouse's own acid-producing cells as well as the bacteria. The Leb mice developed an inflammatory reaction that resembled chronic active gastritis found in humans with symptomatic H. pylori infection. Their parietal cells disappeared, as they do in humans with atrophic gastritis, a precancerous condition. In a different study, Gordon's group has shown that undifferentiated cells in the stomach lining proliferate abnormally when parietal cells are lost. Such unrestrained cell division eventually may increase the risk of cancer, Gordon suggests. "So though attachment isn't necessary for H. pylori infection, it markedly affects the outcome of infection," he says.

This genetically well-defined model should enable researchers to identify bacterial and host genes that respond to attachment. Such information should further treatment and prevention efforts. Gordon suggests that his group's approach also could be used with other types of bacteria to understand the role of bacterial attachment in a variety of diseases. "This melding of transgenic mice and molecular microbiology offers great opportunities for the future," he says.

Guruge JL, Falk PG, Lorenz RG, Dans M, Wirth H-P, Blaser MJ, Berg DE, Gordon JI. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proceedings of the National Academy of Sciences, 95, 3925-3930, 1998

This research was supported by grants from the National Institutes of Health and the Swedish Cancer Society.


Story Source:

The above story is based on materials provided by Washington University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Washington University School Of Medicine. "Researchers Discover Ways The Ulcer/Cancer Bug Can Trigger Disease." ScienceDaily. ScienceDaily, 6 April 1998. <www.sciencedaily.com/releases/1998/04/980406073530.htm>.
Washington University School Of Medicine. (1998, April 6). Researchers Discover Ways The Ulcer/Cancer Bug Can Trigger Disease. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/1998/04/980406073530.htm
Washington University School Of Medicine. "Researchers Discover Ways The Ulcer/Cancer Bug Can Trigger Disease." ScienceDaily. www.sciencedaily.com/releases/1998/04/980406073530.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins